

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

			on, D.C. 2023 i	all .
FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
9 01/11/0	O BOMAN		B	CATX-N
- 024988 HM12/03		一		EXAMINER
LEONA L LAUDER			DAVIS,M	
369 PINE STREET			ART UNIT	PAPER NUMBER
ISCO CA 941	04-3313		1642 DATE MAILED:	1 <i>O</i> .
	O1/11/0 AUDER STREET	9 01/11/00 BOMAN HM12/0330 AUDER	O1/11/00 BOMAN HM12/0330 AUDER STREET	9 01/11/00 BOMAN B HM12/0330 AUDER STREET SSC0 CA 94104-3313 1642

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No 389 09/480,398

Applicant(s)

Boman et al

Examiner

Minh-Tam Davis

Group Art Unit 1642



X Responsive to communication(s) filed on <u>Dec 19, 2000</u>	
☐ This action is FINAL .	
Since this application is in condition for allowance except in accordance with the practice under <i>Ex parte Quayle</i> , 19	935 C.D. 11; 453 O.G. 213.
A shortened statutory period for response to this action is se is longer, from the mailing date of this communication. Failu application to become abandoned. (35 U.S.C. § 133). Exter 37 CFR 1.136(a).	re to respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	
☐ Claim(s)	is/are rejected.
Claim(s)	· ·
	are subject to restriction or election requirement.
Application Papers See the attached Notice of Draftsperson's Patent Drav	ving Review, PTO-948.
☐ The drawing(s) filed on is/are obj	
☐ The proposed drawing correction, filed on	
The specification is objected to by the Examiner.	
The oath or declaration is objected to by the Examiner	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign prior	ity under 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies	
received.	
received in Application No. (Series Code/Serial	Number)
\square received in this national stage application from t	the International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:	
Acknowledgement is made of a claim for domestic pri	iority under 35 U.S.C. § 119(e).
Attachment(s)	
☐ Notice of References Cited, PTO-892	
☐ Information Disclosure Statement(s), PTO-1449, Pape	r No(s)
☐ Interview Summary, PTO-413	0.048
☐ Notice of Draftsperson's Patent Drawing Review, PTO	J-340
☐ Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION C	ON THE FOLLOWING PAGES

Application/Control Number: 09/480389 Page 2

Art Unit: 1642

DETAILED ACTION

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group I. Claims 1-48, drawn to a method for detecting a disease comprising determining whether no wild-type protein expressed by a subject gene is present in a sample, due to mutation in each of the alleles of said subject gene, classified in class 435, subclass 7.1.

Group II. Claims 1-48, drawn to a method for detecting a disease comprising determining whether there is an abnormal low level of wild-type protein expressed by a subject gene in a sample, due to mutation in one of the alleles of said subject gene, classified in class 435, subclass 7.1.

In addition, upon the election of any of groups !-II, further election of the following patentably distinct species of the claimed invention is required:

- 1) Germline mutations or somatic mutations.
- 2) Any one of the biological samples recited in claim 9.
- 3) Any one of the detection methods recited in claim 22.
- 4) Any one of the genes recited in claims 16, 38 and 41.
- 5) Any one of the disease recited in claim 17 and 39.

Upon election of the species body fluids, further election of the following patentably distinct species of the claimed invention is required:

Application/Control Number: 09/480389 Page 3

Art Unit: 1642

Any one of the body fluid recited in claim 10.

2. The inventions are distinct, each from the other because of the following reasons:

The method of groups I is distinct from the method of groups II, because loosing one allele of a gene could result in different diseases and/or disease conditions and disease susceptability, as compared to loosing both alleles of a gene, in which the protein encoded by said gene is complety lost, and because the methods differ at least in method steps, based on different expression properties of a gene.

Further, different types of mutations are patentably distinct because different type of mutation could result in different diseases and/or disease conditions and disease susceptability.

Different genes are patentably distinct because they are structurally distinct.

The species germline mutations and somatic mutations are distinct because they involve different sites of mutation.

The species biological samples and body fluids are distinct because they are different biochemicals with different properties.

The species methods of detection are patentably distinct because they use different method steps, reagents and/or dosages.

Different diseases are patentably distinct because they are

Because these inventions are distinct for the reason given above and have acquired a separate status in the art, and because the searches for the groups are not co-extensive, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/480389 Page 4

Art Unit: 1642

Applicants are required under 35 USC 121 to elect a single disclosed group for prosecution on the merits to which the claims shall be restricted. Applicant is further advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 USC 103 of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Minh-Tam B. Davis whose telephone number is (703) 305-2008. The examiner can normally be reached on Monday-Friday from 9:30am to 3:30pm, except on Wesnesday.

Application/Control Number: 09/480389

Page 5

Art Unit: 1642

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tony Caputa, can be reached on (703) 308-3995. The fax phone number for this Group is (703) 308-4227.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0916.

Minh-Tam B. Davis

March 22, 2001